Therapeutic Effectiveness of Galphimia glauca vs. Lorazepam in Generalized Anxiety Disorder. A Controlled 15-Week Clinical Trial

Planta Medica ◽  
2012 ◽  
Vol 78 (14) ◽  
pp. 1529-1535 ◽  
Author(s):  
Armando Herrera-Arellano ◽  
Jesus Jiménez-Ferrer ◽  
Alejandro Zamilpa ◽  
Griselda García-Alonso ◽  
Sara Herrera-Alvarez ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Anxiety Disorder ◽  
Generalized Anxiety Disorder ◽  
Generalized Anxiety ◽  
Therapeutic Effectiveness

Cognitive Behavior Therapy Targeting Intolerance of Uncertainty Versus Selective Serotonin Reuptake Inhibitor for Generalized Anxiety Disorder: A Randomized Clinical Trial

2021 ◽  
pp. 1-13 ◽  
Author(s):  
Mehdi Zemestani ◽  
Negar Beheshti ◽  
Farzin Rezaei ◽  
Colin van der Heiden ◽  
Philip C. Kendall
Keyword(s):  
Clinical Trial ◽  
Anxiety Disorder ◽  
Generalized Anxiety Disorder ◽  
Behavior Therapy ◽  
Cognitive Behavior Therapy ◽  
Serotonin Reuptake ◽  
Intolerance Of Uncertainty ◽  
Selective Serotonin ◽  
Generalized Anxiety ◽  
Cognitive Behavior

Abstract Given the high prevalence and adverse outcomes associated with generalized anxiety disorder (GAD), development and expansion of effective treatment modalities are important. The present study compared the effectiveness of cognitive behavior therapy targeting intolerance of uncertainty (CBT-IU) and selective serotonin reuptake inhibitors (SSRIs) for treating GAD. A total of 30 Iranian patients with GAD (Mage = 25.16 ± 6.73) were randomised to receive either CBT-IU (n = 15) or SSRI (n = 15). Measures included the Structured Clinical Interview for DSM-5 (SCID-5), Penn State Worry Questionnaire (PSWQ), Why Worry-II (WW-II), Intolerance of Uncertainty Scale (IUS), and Negative Problem Orientation Questionnaire (NPOQ). Repeated measures analysis of variance tested differential treatment outcomes. The results of intention-to-treat (ITT) analysis indicated that although both CBT-IU and SSRI were effective treatments for GAD, CBT-IU produced significantly better results than SSRI at post-treatment. This clinical trial provides preliminary cross-cultural support for the treatment of GAD using CBT-IU, with findings suggesting that this non-medication intervention reduces GAD symptoms.

Transcranial direct current stimulation for the treatment of generalized anxiety disorder: A randomized clinical trial

2019 ◽  
Vol 259 ◽  
pp. 31-37 ◽  
Author(s):  
Ana Lucia de Lima ◽  
Francisco Moisés Azevedo Braga ◽  
Rodrigo Maciel Medeiros da Costa ◽  
Elihab Pereira Gomes ◽  
André Russowsky Brunoni ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Anxiety Disorder ◽  
Randomized Clinical Trial ◽  
Generalized Anxiety Disorder ◽  
Direct Current ◽  
Transcranial Direct Current Stimulation ◽  
Generalized Anxiety ◽  
Direct Current Stimulation

scholarly journals Gender-specific prevalence and associated factors of major depressive disorder and generalized anxiety disorder in a Chinese rural population: the Henan rural cohort study

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Zhicheng Luo ◽  
Yuqian Li ◽  
Yitan Hou ◽  
Xiaotian Liu ◽  
Jingjing Jiang ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Major Depressive Disorder ◽  
Cohort Study ◽  
Anxiety Disorder ◽  
Depressive Disorder ◽  
Generalized Anxiety Disorder ◽  
Associated Factors ◽  
Generalized Anxiety ◽  
Major Depressive ◽  
Gender Specific

Abstract Background This study aims to investigate the prevalence and associated factors of major depressive disorder (MDD) and generalized anxiety disorder (GAD) by gender in Chinese rural adults. Methods A total of 29,993 participants aged from 18 to 79 years from the Henan Rural Cohort Study were included in this study. The Patient Health Questionnaire-2 (PHQ-2) and Generalized Anxiety Disorder-2 (GAD-2) were used to assess MDD and GAD through a face-to-face interview. Multivariate logistic regression model was conducted to analyze the associated factors for MDD and GAD. Results The age-standardized prevalence of MDD and GAD (and 95%CI) in the total sample were 5.41% (5.17–5.66%) and 4.94% (4.71–5.18%), respectively. Besides, the crude prevalence in women were significantly higher than men for both MDD (6.81% vs. 4.77%) and GAD (6.63% vs. 3.93%) (both P < 0.001). Tetrachoric correlation test showed high comorbidity between MDD and GAD (r = 0.88, P = 0.01). Further analysis revealed that age, sex, marital status, educational level, per capita monthly income, drinking, physical activity, and body mass index were associated with MDD and GAD in the overall sample. Gender difference was found among age groups for MDD (Pinteraction < 0.001). Conclusions These findings showed that Chinese rural adults were at low risk for prevalence of MDD and GAD. Women had higher prevalence and risks for MDD and GAD compared with men, indicating that women deserved more attention. Gender-specific interventions on the modifiable associated factors are urgently needed to improve the mental conditions for Chinese rural population. Clinical trial registration The Henan Rural Cohort Study has been registered in the Chinese Clinical Trial Register (Registration number: ChiCTR-OOC-15006699). Date of registration: 2015-07-06.

scholarly journals Yoga for generalized anxiety disorder: design of a randomized controlled clinical trial

2015 ◽  
Vol 44 ◽  
pp. 70-76 ◽  
Author(s):  
Stefan G. Hofmann ◽  
Joshua Curtiss ◽  
Sat Bir S. Khalsa ◽  
Elizabeth Hoge ◽  
David Rosenfield ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Anxiety Disorder ◽  
Generalized Anxiety Disorder ◽  
Controlled Clinical Trial ◽  
Generalized Anxiety ◽  
Randomized Controlled Clinical Trial ◽  
Randomized Controlled

scholarly journals Predictors of change in quality of life in older adults with generalized anxiety disorder

2014 ◽  
Vol 27 (7) ◽  
pp. 1207-1215 ◽  
Author(s):  
Srijana Shrestha ◽  
Melinda A. Stanley ◽  
Nancy L. Wilson ◽  
Jeffrey A. Cully ◽  
Mark E. Kunik ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Social Support ◽  
Older Adults ◽  
Clinical Trial ◽  
Anxiety Disorder ◽  
Randomized Clinical Trial ◽  
Generalized Anxiety Disorder ◽  
Generalized Anxiety ◽  
Over Time

ABSTRACTBackground:Quality of life (QOL) is lower in older adults with generalized anxiety disorder (GAD). QOL generally improves following cognitive-behavioral treatment for GAD. Little is known, however, about additional variables predicting changes in QOL in older adults with GAD. This study examined predictors of change in QOL among older participants in a randomized clinical trial of cognitive behavioral therapy (CBT) for GAD, relative to enhanced usual care (EUC).Methods:Hierarchical multilevel mixed-model analyses were used to examine inter-individual and intra-individual factors that predicted QOL over time. Predictors were categorized into treatment, personal and clinical characteristics.Results:QOL improved over time, and there was significant variability between participants in change in QOL. Controlling for treatment condition, baseline general self-efficacy, baseline social support, within-person variation in worry and depression and average levels of depression across different time points predicted changes in QOL.Conclusions:QOL has increasingly been used as an outcome measure in treatment outcome studies to focus on overall improvement in functioning. Attention to improvement in symptoms of depression and worry, along with psychosocial variables, such as social support and self-efficacy, may help improve QOL in older adults with GAD.This study was a secondary study of data from a randomized clinical trial (NCT00308724) registered with clinical.trials.gov.

scholarly journals Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder

2013 ◽  
Vol 16 (1) ◽  
pp. 1-11 ◽  
Author(s):  
David Michelson ◽  
Richard Hargreaves ◽  
Robert Alexander ◽  
Paulette Ceesay ◽  
Jarmo Hietala ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Anxiety Disorder ◽  
Substance P ◽  
Generalized Anxiety Disorder ◽  
Receptor Occupancy ◽  
Generalized Anxiety ◽  
Proof Of Concept ◽  
Nk1 Receptor ◽  
Neurokinin 1 ◽  
Nk1 Receptor Antagonists

Abstract Preclinical studies suggest that substance P acting at neurokinin 1 (NK1) receptors may be involved in stress responses and NK1 receptor antagonists show activity in tests of anxiety. These data raise the possibility that NK1 receptor antagonists could be potential anxiolytic treatments in humans. We evaluated this hypothesis clinically using the NK1 antagonist L-759274. This is a randomized, double-blind, placebo- and active-controlled, multicentre, proof-of-concept trial. Patients with generalized anxiety disorder were randomized 1:1:1 to 6 wk of treatment with 40 mg L-759274 (n = 73), 1–6 mg lorazepam (n = 69) or placebo (n = 71). Efficacy was assessed using the Hamilton Anxiety Scale (HAMA). A positron emission tomography (PET) study was also performed in 16 healthy subjects to determine the relationship between NK1 receptor occupancy and plasma levels of L-759274 to verify adequate target engagement by the doses tested during the clinical trial. No statistically significant difference in mean change from baseline HAMA score at 6 wk was seen for L-759274 vs. placebo [difference = 1.0 (95% confidence intervals (CI) −1.2 to 3.2), p = 0.359] whereas the lorazepam group did show a significant improvement vs. placebo (difference = −2.7, 95% CI −5.0 to −0.4, p = 0.020) and L-759274 (difference = 3.7, 95% CI 1.5–6.0, p = 0.001]. Results from the PET study indicated that the L-759274 dosing regimen used in the clinical trial likely provided high levels of NK1 receptor occupancy (>90%), supporting the view that it was an adequate proof-of-concept trial. The NK1 receptor antagonist L-759274 does not appear to be efficacious for the treatment of generalized anxiety disorder.

Sign in / Sign up

Export Citation Format

Share Document